gradientech

Next: QuickMIC® GN02
Expanded Gram-negative AST for Highly Resistant Pathogens

Rapid MIC in 2-4 Hours Directly From Positive Blood Cultures

The data presented are based on preliminary findings[1]. Further studies and additional data are required to fully validate the performance of the final QuickMIC® GN02 panel configuration.

QuickMIC® GN02 in development

QuickMIC GN02 will broaden Gram-negative antibiotic coverage with advanced, resistance-targeted agents designed to overcome key β-lactam resistance mechanisms. This will enable rapid phenotypic AST directly from positive blood cultures, supporting timely and effective treatment of infections caused by multidrug-resistant Gram-negative pathogens.

Expanded antibiotic coverage

Designed for today's antimicrobial resistance challenges, QuickMIC GN02 is focused on newer antibiotics and inhibitor combinations, including cefiderocol, ceftolozane/tazobactam, meropenem/vaborbactam, and aztreonam/avibactam.

Cefiderocol spotlight

Cefiderocol is a siderophore cephalosporin used as a last-resort therapy against resistant Gram-negative pathogens. Preliminary QuickMIC data suggests **rapid phenotypic AST** may be feasible directly from positive blood culture, with cefiderocol MIC results available in ~3.5 hours.

From testing challenge to rapid results

- Testing cefiderocol using conventional automated AST systems is challenging because the antibiotic requires non-standard testing conditions with specialised iron-depleted media.
- Preliminary data indicates that QuickMIC allows testing without the need for specialised iron-depleted media, supporting susceptibility testing for this critical therapy.

QuickMIC® GN02:

- Amikacin
- Aztreonam/avibactam
- Cefepime
- Cefiderocol
- Ceftazidime
- Ceftazidime/avibactam
- Ceftolozane/tazobactam
- Ciprofloxacin
- Colistin
- Meropenem
- Meropenem/vaborbactam
- Piperacillin/tazobactam

Cefiderocol results from performance testing



QuickMIC® data shows >90% Categorical Agreement for cefiderocol on a resistant challenge dataset exceeding 20 carbapenemase-producing E.coli[1].

[1]Åman A, Chatzopoulou M, Öhrn H, Faxén L, Johansson C, Olsson A, Lagerbäck P, Tängdén T, Malmberg C. Rapid susceptibility testing of cefiderocol directly from positive blood cultures using a microfluidic agar-diffusion. ESCMID Global 2025, P1550, April 2025.

QuickMIC® GN02 supports susceptibility testing of newer antibiotics and inhibitor combinations for Gram-negative pathogens in clinical microbiology laboratories.

Gradientech | Uppsala Science Park, 751 83, Sweden | sales@gradientech.se | www.gradientech.se

MAR074-01